Schizophrenia Market is Expected to Showcase a Significant Growth During the Forecast Period (2023-2032), Predicts DelveInsight | Avanir, Autifony, Ironwood Pharma, Boehringer Ingelheim, Takeda, Addex, Merck, MapLight Therapeutics, Roche, Otsuka

The Schizophrenia Market is anticipated to grow in the coming years owing to the increasing prevalent population of schizophrenia patients in the 7MM and the expected entry of emerging products in the market.

DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Schizophrenia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Schizophrenia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Schizophrenia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Schizophrenia: An Overview
Schizophrenia is a severe mental illness that interferes with a person's ability to think, manage emotions, make decisions, and relate to others. Schizophrenia symptoms can differ from person to person, but they generally fall into three main categories: psychotic, negative, and cognitive.

Negative symptoms include loss of motivation, loss of interest or enjoyment in daily activities, withdrawal from social life, difficulty showing emotions, and difficulty functioning normally. Cognitive symptoms include problems in attention, concentration, and memory. These symptoms can make it hard to follow a conversation, learn new things, or remember appointments

Schizophrenia is not caused by just one genetic variation but by a complex interplay of genetics and environmental influences. Also, having a history of family psychosis greatly increases the risk.
Medications are the cornerstone of schizophrenia treatment, and antipsychotic medications are the most commonly prescribed drugs. They were thought to control symptoms by affecting the brain neurotransmitter dopamine. High-dose regimens of long-acting injectable (LAI) risperidone, once-monthly paliperidone palmitate, or once-monthly aripiprazole can improve disease severity, hospitalization, and disability outcomes among treated patients with severe, resistant schizophrenia.

Moreover, the leading pharma and biotech companies in the Schizophrenia therapeutics market include Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.

Schizophrenia Market Key Facts
• In 2021, the total Schizophrenia market size was USD 8,664.6 million, which is expected to rise during the study period (2019-2032).
• The total market size of Schizophrenia in the United States was USD 5,203.7 million in 2021.
• In the EU5, the total market size of Schizophrenia was USD 2,547.3 million in 2021.
• In 2021, the Schizophrenia prevalent cases were found to be around 6.27 million in the 7MM.
• In the year 2021, the total prevalent cases of Schizophrenia were 1.08 million cases in Japan which is expected to grow during the study period, i.e., 2019-2032.
• According to the DelveInsight, in the year 2021, the total prevalent cases of Schizophrenia were 2.97 million in the United States, which is expected to grow during the study period, i.e., 2019-2032.
• EU5 countries occupied approximately 33.8% of the diagnosed patient pool amongst 7MM in 2020.

Discover How Schizophrenia Market Will Grow by 2032:
https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Schizophrenia therapies in the market. It also provides a detailed assessment of the Schizophrenia market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Schizophrenia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Schizophrenia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Schizophrenia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Schizophrenia Epidemiology Segmented as -
• Prevalent Cases of schizophrenia in the 7MM (2019-32)
• Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
• Age-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
• Gender-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
• Severity-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)

Get Key Insights Into the Evolving Schizophrenia Epidemiology Trends @
https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to be launched during the study period. The analysis covers the market share by Schizophrenia drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Schizophrenia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Therapeutics Assessment
The major medications used to treat schizophrenia are called antipsychotics. They are generally effective for treating the positive symptoms of schizophrenia. Every person reacts a little differently to antipsychotic drugs, so a patient may need to try several before finding the one that works best. If a medication does help, it is important to continue it even after symptoms improve. Without medication, there is a high likelihood that psychosis will return, and each returning episode might be worse.

There are several FDA-approved products for schizophrenia treatment in the market. Moreover, the pipeline of schizophrenia possesses several potential drugs that are expected to be launched soon. Some of the major potential therapies in the pipeline include Doria (risperidone ISM), Roluperidone (MIN-101), Dexmedetomidine (BXCL501), SEP363856, Pimavanserin, BI 425809, GWP42003-P, KarXT (a fixed combination of xanomeline and trospium chloride), Evenamide, LYN-005, and others.

To improve the treatment scenario, several major pharma and biotech giants are actively working in the Schizophrenia Therapeutics Market. Several major pharma and biotech companies are developing therapies for Schizophrenia. Currently, Otsuka Pharmaceutical is leading the therapeutics segment with its Schizophrenia drug candidates in the most advanced stage of clinical development.

Major Clinical, Commercial, and Regulatory Developments in the Schizophrenia Therapeutics Market
• On January 15, 2023, Luye Pharma Group (Luye Pharma) announced that the U.S. Food and Drug Administration (FDA) had approved Rykindo® (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
• On October 28, 2022, Sosei Group Corporation announced that the first patient had been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia. NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.

Leading Companies in the Schizophrenia Therapeutics Market Include
Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, Karuna Therapeutics, Lyndra Therapeutics, Minerva Neurosciences, Neurocrine Biosciences, Newron Pharmaceuticals, Otsuka Pharmaceuticals, Pharmaceuticals Laboratories, PsychoGenics, Reviva Pharmaceuticals, Sunivion, Takeda, and many others.

Emerging and Marketed Schizophrenia Therapies Covered in the Report Include
• AVP 786: Avanir Pharmaceuticals
• Backup modulators: Autifony Therapeutics
• CY 6463: Ironwood Pharmaceuticals
• Iclepertin: Boehringer Ingelheim
• Luvadaxistat: Takeda
• M4 PAM: Addex Therapeutics
• MK-8189: Merck Sharp & Dohme
• ML-007: MapLight Therapeutics
• Ralmitaront: Roche
• Ulotaront: Otsuka Pharmaceutical
And Many More

Learn More About the Emerging Therapies & Key Companies in the Schizophrenia Therapeutics Market:
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Schizophrenia Competitive Intelligence Analysis
4. Schizophrenia Market Overview at a Glance
5. Schizophrenia Background and Overview
6. Schizophrenia Patient Journey
7. Schizophrenia Epidemiology and Patient Population
8. Schizophrenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Schizophrenia Unmet Needs
10. Key Endpoints of Schizophrenia Treatment
11. Schizophrenia Marketed Products
12. Schizophrenia Emerging Therapies
13. Schizophrenia Seven Major Market Analysis
14. Attribute Analysis
15. Schizophrenia Market Outlook (7 major markets)
16. Schizophrenia Access and Reimbursement Overview
17. KOL Views on the Schizophrenia Market.
18. Schizophrenia Market Drivers
19. Schizophrenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Eczema Market
https://www.delveinsight.com/report-store/eczema-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market

Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market

Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market

Factor Xa Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market

Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market

Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Chronic Periodontitis Market
https://www.delveinsight.com/report-store/chronic-periodontitis-market

Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market

Exocrine Pancreatic Insufficiency Market
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market

Papilloma MarketRespiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market

Sinusitis Market
https://www.delveinsight.com/report-store/sinusitis-market

Childhood Atropine For Myopia Progression Market
https://www.delveinsight.com/report-store/childhood-atropine-for-myopia-progression-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market

Adeno-Associated Virus Vectors in Gene Therapy Market
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.